Nick Knudsen

This inventor holds 37 USPTO granted patents and 9 published patent applications, plus 6 CIPO patents and 14 EPO patents, primarily in Modified Polypeptides. Top assignees: Ambrx, Inc., Merck Sharp + Dohme Corp., Elanco US Inc.. Active years: 2011-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nick Knudsen. Retrieved from https://idiyas.com/inventor/nick-knudsen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 37 (Patent Applications = 9)

% Patents Active = 73.0

CIPO Patents = 6 (Patent Applications = 2)

EPO Patents = 14 (Patent Applications = 20)

Average Co-Inventor Count = 7.1

ph-index = 14

Forward Citations = 412(Granted Patents)

Location History:

La Jolla, CA (US) (2018)
Escondito, CA (US) (2016 - 2019)
San Diego, CA (US) (2011 - 2023)
Escondido, CA (US) (2019 - 2024)

Company Filing History:

Merck Sharp + Dohme Corp.

where one patent can have more than one assignee

Years Active: 2011-2024

Loading Chart...

Areas of Expertise:

Modified FGF-21

Relaxin Polypeptides

Antibody Drug Conjugates

Nucleic Acids

Therapeutic Uses

Modified Insulin

Heart Failure Treatment

Obesity Treatment

Prostate-Specific Antigen

Intracellular Delivery

Recombinant Human Growth Hormone

Pegylated Interferon

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11993637 - Modified FGF-21 polypeptides with non-naturally encoded amino acids (2024-05-28),

2. 11786578 - Modified relaxin polypeptides and their uses (2023-10-17),

3. 11773150 - Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors (2023-10-03),

4. 11542310 - Modified bovine G-CSF polypeptides and their uses (2023-01-03),

5. 11510993 - Antibody drug conjugate for anti-inflammatory applications (2022-11-29),

6. 11459392 - Anti-CD70 antibody drug conjugates (2022-10-04),

7. 11439710 - Nucleic acids encoding modified relaxin polypeptides (2022-09-13),

8. 11311605 - Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides (2022-04-26),

9. 10961291 - Modified FGF-21 polypeptides and their uses (2021-03-30),

10. 10800856 - Prostate-specific membrane antigen antibody drug conjugates (2020-10-13),

11. 10800826 - Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors (2020-10-13),

12. 10751391 - Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid (2020-08-25),

13. 10702588 - Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain (2020-07-07),

14. 10550190 - Phosphate based linkers for intracellular delivery of drug conjugates (2020-02-04),

15. 10377805 - Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses (2019-08-13),

Title: Top Inventor in San Diego

Introduction: Tao Luo is recognized as a leading inventor in San Diego, known for his innovative contributions to various fields.

Latest Patents: His recent patents include advancements in technology and engineering that have garnered attention in the industry.

Career Highlights: Throughout his career, Tao has achieved significant milestones, establishing himself as a prominent figure in the invention landscape.

Collaborations: He has collaborated with various organizations and institutions, enhancing his impact on technological advancements.

Conclusion: Tao Luo continues to inspire future inventors with his groundbreaking work and dedication to innovation.

Profile summary based on public USPTO records.